Lexicon Pharmaceuticals

Lexicon touts significant results for LX4211 phase IIb trial in T2D

Monday, June 25, 2012 03:50 PM

Lexicon Pharmaceuticals of The Woodlands, Texas, has reported that LX4211, an investigational, oral, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), showed substantial, dose-dependent, statistically-significant reductions in hemoglobin A1c (HbA1c) in a phase IIb trial in patients diagnosed with poorly-controlled type 2 diabetes who were concurrently treated with metformin, an established diabetes therapy.

More... »

Lexicon’s LX411 enhances DPP-4 inhibitor in type 2 diabetics

Friday, January 13, 2012 12:09 PM

LX4211, a novel sodium glucose transporter 1 and 2 (SGLT1 and SGLT2) inhibitor, was proven to enhance the affects of widely prescribed diabetes drug sitagliptin, a DDP-4 (dipeptidyl peptidase) inhibitor, reported Lexicon Pharmaceuticals.

More... »

Lexicon’s LX4211 trial shows positive results

Tuesday, September 13, 2011 11:30 AM

Lexicon Pharmaceuticals reported positive data from a recently completed clinical trial and mechanistic study of LX4211, a dual inhibitor of the sodium glucose transporters 1 and 2 (SGLT1 and SGLT2).  The favorable safety profile and effects on multiple parameters of glycemic control and cardiovascular health in healthy normal subjects support the broad potential of LX4211 in the treatment of diabetes and associated metabolic conditions.

More... »

Lexicon’s phase II LX1032 trial shows positive results

Tuesday, August 16, 2011 02:03 PM

Lexicon Pharmaceuticals has reported positive, top-line proof-of-concept data from its recently completed phase II study in carcinoid syndrome with LX1032, telotristat etiprate. Carcinoid syndrome is a chronic condition caused by neuroendocrine tumors that usually originate from the gastrointestinal tract. It is characterized by severe diarrhea and flushing episodes with long-term consequences including malnutrition, heart disease, and death. Symptoms of carcinoid syndrome have been linked to excess production of serotonin by metastatic tumor cells. Telotristat etiprate is designed to reduce serotonin production.

More... »

Lexicon successfully completes phase I LX1033 trial

Friday, July 29, 2011 11:16 AM

Lexicon Pharmaceuticals has successfully completed a phase I clinical trial of LX1033, an orally-delivered small-molecule drug candidate for diarrhea-predominant irritable bowel syndrome (IBS-d).  Lexicon plans to move LX1033 forward into a phase II study in patients with IBS-d.

More... »

Lexicon Pharmaceuticals names Dr. Pablo Lapuerta CMO

Tuesday, March 29, 2011 12:15 PM

Lexicon Pharmaceuticals has named Pablo Lapuerta, M.D., chief medical officer. He will be responsible for directing clinical development of Lexicon's drug candidates from phase II proof-of-concept through phase III and approval.

More... »